• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卡塔尔嗜麦芽窄食单胞菌相关下呼吸道感染的临床与流行病学特征:一项回顾性研究

Clinical and Epidemiological Characteristics of Stenotrophomonas maltophilia Associated Lower Respiratory Tract Infections in Qatar: A Retrospective Study.

作者信息

Nair Arun P, Sasi Sreethish, Al Maslamani Muna, Al-Khal Abdullatif, Chacko Kadavil, Deshmukh Anand, Abukhattab Mohammed

机构信息

Infectious Diseases, Hamad Medical Corporation, Doha, QAT.

Infectious Disease, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, GBR.

出版信息

Cureus. 2022 Mar 17;14(3):e23263. doi: 10.7759/cureus.23263. eCollection 2022 Mar.

DOI:10.7759/cureus.23263
PMID:35449666
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9013242/
Abstract

Background  is a rapidly emerging nosocomial pathogen with intrinsic or acquired resistance mechanisms to several antibiotic classes. It can cause life-threatening opportunistic pneumonia, particularly among hospitalized patients. Incidence of infections by  has been reported as 0.07-0.4% of hospital discharges, but its mortality is 20 -60%. This is the first study from Qatar indexing the clinical and epidemiological characteristics and antibiotic susceptibility of  Materials and methods This retrospective descriptive epidemiological study was conducted in 6 tertiary care hospitals under Hamad Medical Corporation in Doha, Qatar, analyzing inpatient respiratory isolates of during 2016-17. Out-patients, children below 14 years, and non-respiratory samples except blood cultures in patients with pneumonia were excluded. Clinical records were reviewed to identify possible risk factors. Infection and colonization were identified using the Centers for Disease Control and Prevention (CDC) algorithm for clinically defined pneumonia and statistically analyzed using the chi-square test and Pearson's correlation. Results  was isolated from 2.07% (317/15312) of all respiratory samples received in the microbiology lab during our study period. Three hundred seventeen patients studied had a mean age of 60 ± 20 years, and 68% were men. Most of the isolates were from sputum (179), followed by tracheal aspirate (82) and bronchoscopy (42). Fourteen blood culture samples from patients diagnosed with pneumonia were also included. 67% were hospitalized for more than two weeks, 39.1% were on mechanical ventilators, and 88% had received a broad-spectrum antibiotic before the event. 29.1% were deemed to have an infection and 70.9% colonization. Incidence of infection in those with Charlson's Co-morbidity Index (CCI) ≥ 3 was 36.5% compared to 24.2% in those with CCI < 3 (Relative Risk (RR)=1.52; 95% CI: 1.04,2.18; p=0.01). Patients with recent chemotherapy, immunosuppressant, or steroid use had a significantly higher infection risk than those without (69.2% v/s 23.3% RR=2.96; 95% CI:2.2,3.9; p<0.005). The most common symptoms in patients with infection were fever (96%) and expectoration (61.9%). The most common radiological finding was lobar consolidation (71.6%). Mean CRP and procalcitonin were 106.5±15.5 mg/l and 12.3 ± 14 ng/ml. Overall mortality was 16.3%. Patients on mechanical ventilator with IBMP-10 score ≥ 2 had 22.8% mortality compared to 5.7% in those with score < 2 (RR=3.9;95%CI:0.9,16.6; p<0.015). As per The US Clinical and Laboratory Standards Institute (CSLI) breakpoint values, Trimethoprim-Sulfamethoxazole (TMP-SMX) showed the highest sensitivity (97.8%), followed by levofloxacin (71.6%). 0.3% of samples were pan-drug resistant. Conclusions  is a frequent nosocomial colonizer, but it can cause nosocomial pneumonia in almost one-third of cases, specifically in immunocompromised and patients with CCI ≥ 3 with a high risk of mortality due to ventilator-associated pneumonia (VAP) in those with IBMP-10 ≥ 2. Prolonged hospital stay is a risk factor for colonization by  while recent chemotherapy, immunosuppressant, or steroid use are risk factors for hospital-acquired pneumonia due to  TMP-SMX and levofloxacin are the only reliable agents for monotherapy of respiratory infections due to S. maltophilia in Qatar.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdf3/9013242/5f40f005c42b/cureus-0014-00000023263-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdf3/9013242/5f40f005c42b/cureus-0014-00000023263-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdf3/9013242/5f40f005c42b/cureus-0014-00000023263-i02.jpg
摘要

背景 是一种迅速出现的医院病原体,对多种抗生素类具有内在或获得性耐药机制。它可导致危及生命的机会性肺炎,尤其是在住院患者中。据报道, 感染的发生率占医院出院人数的0.07 - 0.4%,但其死亡率为20 - 60%。这是卡塔尔第一项对 的临床和流行病学特征以及抗生素敏感性进行索引的研究。材料与方法 这项回顾性描述性流行病学研究在卡塔尔多哈哈马德医疗公司下属的6家三级护理医院进行,分析了2016 - 17年期间住院患者的呼吸道分离株。排除门诊患者、14岁以下儿童以及肺炎患者除血培养外的非呼吸道样本。查阅临床记录以确定可能的危险因素。使用美国疾病控制与预防中心(CDC)针对临床定义肺炎的算法确定感染和定植情况,并使用卡方检验和皮尔逊相关性进行统计分析。结果 在我们的研究期间,从微生物实验室收到的所有呼吸道样本中, 占2.07%(317/15312)。研究的317名患者平均年龄为60±20岁,68%为男性。大多数分离株来自痰液(179例),其次是气管吸出物(82例)和支气管镜检查样本(42例)。还包括14例诊断为肺炎患者的血培养样本。67%的患者住院时间超过两周,39.1%的患者使用机械通气,88%的患者在事件发生前接受过广谱抗生素治疗。29.1%被认为有感染,70.9%为定植。Charlson合并症指数(CCI)≥3的患者感染发生率为36.5%,而CCI<3的患者为24.2%(相对风险(RR)=1.52;95%置信区间:1.04,2.18;p = 0.01)。近期接受化疗、使用免疫抑制剂或类固醇的患者感染风险显著高于未使用者(69.2%对23.3%,RR = 2.96;95%置信区间:2.2,3.9;p<0.005)。感染患者最常见的症状是发热(96%)和咳痰(61.9%)。最常见的影像学表现是肺叶实变(71.6%)。平均C反应蛋白(CRP)和降钙素原分别为106.5±15.5mg/l和12.3±14ng/ml。总体死亡率为16.3%。机械通气且IBMP - 10评分≥2的患者死亡率为22.8%,而评分<2的患者为5.7%(RR = 3.9;95%置信区间:0.9,16.6;p<0.015)。根据美国临床和实验室标准协会(CSLI)的断点值,甲氧苄啶 - 磺胺甲恶唑(TMP - SMX)显示出最高的敏感性(97.8%),其次是左氧氟沙星(71.6%)。0.3%的样本为泛耐药。结论 是一种常见的医院定植菌,但在近三分之一的病例中可导致医院获得性肺炎,特别是在免疫功能低下以及CCI≥3的患者中,对于IBMP - 10≥2的患者,因呼吸机相关性肺炎(VAP)导致死亡的风险很高。住院时间延长是 定植的危险因素,而近期化疗、使用免疫抑制剂或类固醇是因 导致医院获得性肺炎的危险因素。在卡塔尔,TMP - SMX和左氧氟沙星是治疗嗜麦芽窄食单胞菌引起的呼吸道感染的唯一可靠单药治疗药物。

相似文献

1
Clinical and Epidemiological Characteristics of Stenotrophomonas maltophilia Associated Lower Respiratory Tract Infections in Qatar: A Retrospective Study.卡塔尔嗜麦芽窄食单胞菌相关下呼吸道感染的临床与流行病学特征:一项回顾性研究
Cureus. 2022 Mar 17;14(3):e23263. doi: 10.7759/cureus.23263. eCollection 2022 Mar.
2
Emerging importance of multidrug-resistant Stenotrophomonas maltophilia infections in neonatal intensive care unit in a tertiary center in Turkey.土耳其一家三级中心新生儿重症监护病房中多重耐药嗜麦芽寡养单胞菌感染的重要性日益增加。
Pediatr Neonatol. 2024 Mar;65(2):183-187. doi: 10.1016/j.pedneo.2023.04.019. Epub 2023 Oct 20.
3
Prevalence and Antibiotic Resistance of in Respiratory Tract Samples: A 10-Year Epidemiological Snapshot.呼吸道样本中[具体内容缺失]的患病率及抗生素耐药性:十年流行病学概况
Health Serv Res Manag Epidemiol. 2019 Aug 15;6:2333392819870774. doi: 10.1177/2333392819870774. eCollection 2019 Jan-Dec.
4
Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals.甲氧苄啶-磺胺甲恶唑与左氧氟沙星治疗感染的比较:一项对美国154家医院电子健康记录的回顾性疗效研究
Open Forum Infect Dis. 2022 Jan 17;9(2):ofab644. doi: 10.1093/ofid/ofab644. eCollection 2022 Feb.
5
The Activities of Antimicrobials Against Isolates and Evaluation of Clinical Outcomes Among Treatment Regimens in Patients with Infections: A Retrospective Multicenter Cohort Study.抗菌药物对感染患者分离株的活性及不同治疗方案临床结局的评估:一项回顾性多中心队列研究
Infect Drug Resist. 2023 Aug 9;16:5173-5184. doi: 10.2147/IDR.S416678. eCollection 2023.
6
Emergence of concurrent levofloxacin- and trimethoprim/sulfamethoxazole-resistant Stenotrophomonas maltophilia: Risk factors and antimicrobial sensitivity pattern analysis from a single medical center in Taiwan.嗜麦芽寡养单胞菌同时耐左氧氟沙星和复方磺胺甲噁唑的出现:来自台湾单一医疗中心的危险因素和抗菌药物敏感性分析。
J Microbiol Immunol Infect. 2022 Feb;55(1):107-113. doi: 10.1016/j.jmii.2020.12.012. Epub 2021 Jan 13.
7
Molecular epidemiology and risk factors of Stenotrophomonas maltophilia infections in a Chinese teaching hospital.中国教学医院嗜麦芽窄食单胞菌感染的分子流行病学和危险因素。
BMC Microbiol. 2020 Sep 29;20(1):294. doi: 10.1186/s12866-020-01985-3.
8
Stenotrophomonas maltophilia in Lower Respiratory Tract Infections.嗜麦芽窄食单胞菌在下呼吸道感染中的情况
J Clin Diagn Res. 2014 Dec;8(12):DC20-2. doi: 10.7860/JCDR/2014/10780.5320. Epub 2014 Dec 5.
9
Stenotrophomonas maltophilia bacteremia in children: risk factors and mortality rate.嗜麦芽寡养单胞菌菌血症在儿童中的:危险因素和死亡率。
Antimicrob Resist Infect Control. 2021 Jan 22;10(1):19. doi: 10.1186/s13756-021-00888-w.
10
Trimethoprim-sulfamethoxazole versus levofloxacin for the treatment of Stenotrophomonas maltophilia infections: A multicentre cohort study.复方磺胺甲噁唑与左氧氟沙星治疗嗜麦芽窄食单胞菌感染的多中心队列研究。
J Glob Antimicrob Resist. 2024 Sep;38:42-48. doi: 10.1016/j.jgar.2024.05.016. Epub 2024 May 30.

引用本文的文献

1
Global mapping of antibiotic resistance rates among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis.全球临床分离嗜麦芽寡养单胞菌耐药率的地图绘制:系统评价和荟萃分析。
Ann Clin Microbiol Antimicrob. 2024 Mar 19;23(1):26. doi: 10.1186/s12941-024-00685-4.

本文引用的文献

1
Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens.米诺环素对不常见的临床重要革兰氏阴性病原体的活性。
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0126421. doi: 10.1128/AAC.01264-21. Epub 2021 Sep 7.
2
Risk factors for 30-day mortality among patients with bacteraemia.菌血症患者30天死亡率的危险因素。
Infect Dis (Lond). 2020 Jun;52(6):440-442. doi: 10.1080/23744235.2020.1734653. Epub 2020 Mar 3.
3
Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole.
潜在替代治疗剂对左氧氟沙星和/或复方磺胺甲噁唑不敏感的嗜麦芽窄食单胞菌分离株的活性。
J Clin Microbiol. 2020 Jan 28;58(2). doi: 10.1128/JCM.01603-19.
4
Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.成人社区获得性肺炎诊断和治疗。美国胸科学会和美国传染病学会的官方临床实践指南。
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST.
5
Prevalence and Antibiotic Resistance of in Respiratory Tract Samples: A 10-Year Epidemiological Snapshot.呼吸道样本中[具体内容缺失]的患病率及抗生素耐药性:十年流行病学概况
Health Serv Res Manag Epidemiol. 2019 Aug 15;6:2333392819870774. doi: 10.1177/2333392819870774. eCollection 2019 Jan-Dec.
6
as an Emerging Ubiquitous Pathogen: Looking Beyond Contemporary Antibiotic Therapy.作为一种新兴的泛在病原体:超越当代抗生素疗法的探索
Front Microbiol. 2017 Nov 30;8:2276. doi: 10.3389/fmicb.2017.02276. eCollection 2017.
7
Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.嗜麦芽窄食单胞菌引起的感染最新情况,特别关注耐药机制和治疗选择。
Front Microbiol. 2015 Sep 2;6:893. doi: 10.3389/fmicb.2015.00893. eCollection 2015.
8
Resistance of Stenotrophomonas maltophilia to Fluoroquinolones: Prevalence in a University Hospital and Possible Mechanisms.嗜麦芽窄食单胞菌对氟喹诺酮类药物的耐药性:某大学医院的发生率及可能机制
Int J Environ Res Public Health. 2015 May 13;12(5):5177-95. doi: 10.3390/ijerph120505177.
9
Risk factors and outcomes of Stenotrophomonas maltophilia bacteraemia: a comparison with bacteraemia caused by Pseudomonas aeruginosa and Acinetobacter species.嗜麦芽窄食单胞菌血症的危险因素及结局:与铜绿假单胞菌和不动杆菌属所致菌血症的比较
PLoS One. 2014 Nov 6;9(11):e112208. doi: 10.1371/journal.pone.0112208. eCollection 2014.
10
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012.2009-2012 年美国和欧洲医院住院肺炎患者分离的革兰氏阴性菌的抗菌药物敏感性:来自 SENTRY 抗菌监测计划的结果。
Int J Antimicrob Agents. 2014 Apr;43(4):328-34. doi: 10.1016/j.ijantimicag.2014.01.007. Epub 2014 Feb 7.